FDA Announces Proposed Collection of Information for Postmarketing Adverse Event Reporting During Influenza Pandemic

Summary

The Food and Drug Administration (FDA) is announcing a proposed collection of information for review and clearance under the Paperwork Reduction Act of 1995, related to postmarketing adverse event reporting for medical products and dietary supplements during an influenza pandemic, and is seeking public comment.